Phase 3
Completed N=540
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
Covid19 · Progression
Source: ClinicalTrials.gov NCT04491994 ↗
Enrolled (actual)
540
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Number of Participants With Progression — 5; 11 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance.
Condition or disease :I COVID-19 ntervention/treatment :Drug: Hydroxychloroquine Sulfate Phase: Phase III
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Progression |
5; 11 | — |
| SECONDARY Viral Clearance |
— | — |
Eligibility Criteria
Inclusion Criteria
- Mild Corona virus disease (COVID-19)
- PCR confirmed infection
- Hospital admitted patients
Exclusion Criteria
- Moderate, severe and critical COVID-19
- day 0 CRP greater than 6mg/dl, ALC < 1000 or evidence of infiltrates on X-ray chest
- comorbidity with life expectancy less than 6 months
- Contraindications to HCQ therapy
Data sourced from ClinicalTrials.gov (NCT04491994). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.